Fundraising Fox원진바이오테크놀로지
Suwon, KR · 1 known investors
Find your way into 원진바이오테크놀로지
Sign up to see every warm intro you have to 원진바이오테크놀로지
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 원진바이오테크놀로지 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.
Founders & leadership
SP
SungJin ParkCEOHe began leading Onegene Group and ONEGENE Biotechnology in 2016, following a research career in the United States. He worked as a postdoctoral fellow and postdoctoral associate at Northwestern University, including the Feinberg School of Medicine, from 2010 to 2016, after serving as a research assistant at the University of North Carolina at Chapel Hill from 2005 to 2010.
Investors · 1
Related companies · 2
OrigeneOriGene develops and manufactures research and diagnostic products, including large-scale GMP antibody production, with R&D and research manufacturing operations. It serves the life sciences and biotech research market from facilities in the US and Germany.
One BiosciencesOneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development. The platform delivers tumor intelligence reports with functional signatures for precision oncology within two weeks.
Companies working in the same space as 원진바이오테크놀로지.
Frequently asked questions
- What does 원진바이오테크놀로지 do?
- Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.
- Who founded 원진바이오테크놀로지?
- 원진바이오테크놀로지 was founded by SungJin Park.
- Who are 원진바이오테크놀로지's investors?
- 원진바이오테크놀로지's investors include Solidus Investment.
- Where is 원진바이오테크놀로지 headquartered?
- 원진바이오테크놀로지 is headquartered in Suwon, KR.